Yiyu Zou, Ph.D.

Medicine

Phone718-430-4146
Emailyiyu.zou@einstein.yu.edu
Websitehttp://www.einstein.yu.edu/faculty/9009/yiyu-zou/

Source: Scopus
Calculated based on no. of publications stored in Pure and citations from Scopus

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint

Dive into the research topics where Yiyu Zou is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

5 Similar Profiles

Network

Recent external collaboration on country level. Dive into details by clicking on the dots.

2 Finished

Inhaled DNA demethylating therapy for lung cancer and bronchial premalignancy
Zou, Y., Perez-Soler, R., Perez-Soler, R., Zou, Y. & Perez-Soler, R.
National Cancer Institute
2/15/11 → 1/31/18
Project: Research project
A Tumor Specific Therapy Approach for Small Cell Lung Cancer
Zou, Y.
National Cancer Institute
7/1/06 → 6/30/07
Project: Research project

3748 Citations
25 h-Index
59 Article
4 Comment/debate
2 Review article

Ascorbic acid–induced TET activation mitigates adverse hydroxymethylcytosine loss in renal cell carcinoma
Shenoy, N., Bhagat, T. D., Cheville, J., Lohse, C., Bhattacharyya, S., Tischer, A., Machha, V., Gordon-Mitchell, S., Choudhary, G., Wong, L. F., Gross, L. A., Ressigue, E., Leibovich, B., Boorjian, S. A., Steidl, U., Wu, X., Pradhan, K., Gartrell, B., Agarwal, B., Pagliaro, L. & 8 others, Suzuki, M., Greally, J. M., Rakheja, D., Houston Thompson, R., Susztak, K., Witzig, T., Zou, Y. & Verma, A., Apr 1 2019, In : Journal of Clinical Investigation. 129, 4, p. 1612-1625 14 p.
Research output: Contribution to journal › Article

Open Access
11 Scopus citations
Lactate-mediated epigenetic reprogramming regulates formation of human pancreatic cancer-associated fibroblasts
Bhagat, T. D., Von Ahgrens, D., Dawlaty, M., Zou, Y., Baddour, J., Achreja, A., Zhao, H., Yang, L., Patel, B., Kwak, C., Choudhary, G. S., Gordon-Mitchell, S., Alluri, S., Bhattacharyya, S., Sahu, S., Yu, Y., Bartenstein, M., Giricz, O., Suzuki, M., Sohal, D. & 12 others, Gupta, S., Guerrero, P., Batra, S., Goggins, M., Steidl, U., Greally, J., Agarwal, B., Pradhan, K., Banerjee, D., Nagrath, D., Maitra, A. & Verma, A., Oct 2019, In : eLife. 8, e50663.
Research output: Contribution to journal › Article

Open Access
10 Scopus citations
PAK kinase inhibition has therapeutic activity in novel preclinical models of adult T-Cell leukemia/lymphoma
Chung, E. Y., Mai, Y., Shah, U. A., Wei, Y., Ishida, E., Kataoka, K., Ren, X., Pradhan, K., Bartholdy, B., Wei, X., Zou, Y., Zhang, J., Ogawa, S., Steidl, U., Zang, X., Verma, A., Janakiram, M. & Ye, B. H., Jun 15 2019, In : Clinical Cancer Research. 25, 12, p. 3589-3601 13 p.
Research output: Contribution to journal › Article
2 Scopus citations
Notch pathway is activated via genetic and epigenetic alterations and is a therapeutic target in clear cell renal cancer
Bhagat, T. D., Zou, Y., Huang, S., Park, J., Palmer, M. B., Hu, C., Li, W., Shenoy, N., Giricz, O., Choudhary, G., Yu, Y., Ko, Y. A., Izquierdo, M. C., Park, A. S. D., Vallumsetla, N., Laurence, R., Lopez, R., Suzuki, M., Pullman, J., Kaner, J. & 8 others, Gartrell, B., Hakimi, A. A., Greally, J. M., Patel, B., Benhadji, K., Pradhan, K., Verma, A. & Susztak, K., Jan 20 2017, In : Journal of Biological Chemistry. 292, 3, p. 837-846 10 p.
Research output: Contribution to journal › Article
15 Scopus citations
Pax5 Re-expression in H460 cells treated with the combination of demethylating agent and histone deacetylase inhibitor is associated with the enhancement of P53 binding to Pax5 promoter region
Liang, Y., Zeng, J., Jelicks, L. A., Ma, S., Liu, J., Mei, J., Perez-Soler, R. & Zou, Y., Feb 1 2017, In : Current Cancer Drug Targets. 17, 2, p. 169-176 8 p.
Research output: Contribution to journal › Review article
1 Scopus citations

Inhaled DNA demethylating therapy for lung cancer and bronchial premalignancy

A Tumor Specific Therapy Approach for Small Cell Lung Cancer

Ascorbic acid–induced TET activation mitigates adverse hydroxymethylcytosine loss in renal cell carcinoma

Lactate-mediated epigenetic reprogramming regulates formation of human pancreatic cancer-associated fibroblasts

PAK kinase inhibition has therapeutic activity in novel preclinical models of adult T-Cell leukemia/lymphoma

Notch pathway is activated via genetic and epigenetic alterations and is a therapeutic target in clear cell renal cancer

Pax5 Re-expression in H460 cells treated with the combination of demethylating agent and histone deacetylase inhibitor is associated with the enhancement of P53 binding to Pax5 promoter region